-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Selective Superoxide Dismistase (SOD) simulator GC4419 is designed to quickly convert superoxides into hydrogen peroxide and oxygen, thus protecting normal tissues from radiation therapy-related damage.
If left untreated, elevated superoxides can damage non-cancerous tissue and lead to debilitating side effects, including oral mucositis (OM), which may limit the anti-tumor efficacy of radiation therapy.
based on positive results from a variety of preclinical models, GC4419 has potential anti-cancer synergies.
pharmaceutical company Galera recently announced that GC4419 in the joint SBRT treatment of advanced pancreatic cancer Phase I/II clinical trials have been positive data.
in the study's intentional treatment queue (n s 19), the total survival of the middle of patients in the GC4419 group (GC4419 plus SBRT) was compared to 40.4 weeks in the placebo (placebo sBRT) group The period (OS) has not yet been reached (HR s 0.3, 95% CI 0.09-1.05, p s 0.046), and the GC4419 group also showed a good progress-free lifetime.
, President and CEO of Galera, said: "There are limited treatment options for pancreatic cancer patients.
by combining our research-based ambiguity enzyme simulations with SBRT, we believe we have the opportunity to improve tumor response and survival outcomes."
.
